Structural Activity Relationship based Medicinal Perspectives of Pyrimidine Derivatives as Anti-Alzheimer's Agents: A Comprehensive Review / Subham Das, Saleem Akbar, Bahar Ahmed, Rikeshwar Prasad Dewangan, Ashif Iqubal, Faheem Hyder Pottoo, Alex Joseph
Pyrimidine is an aromatic and heterocyclic organic compound containing a 6-membered ring consisting of four carbon and two nitrogen atoms on alternative positions. Pyrimidine scaffolds described their existence in the medicinal chemist’s cause for their synthesizing practicability and nonpoisonous nature. However, the reason behind neurological disorders is still an open challenge for scientific research and development organizations. Efficacy voids are widespread before researchers, despite high throughput research in the field of anti-Alzheimer's drugs.Researchers have constantly investigated all the probabilities for restraining the unwanted adverse effects of the anti-Alzheimer’s agents and are focusing more extensively to rehabilitate neurological disorders. The scientific literature on drug development has been an aspiration to medicinal chemists and other researchers to facilitate further research. Therefore, this review emphasizes the structure-activity relationship (SAR) based approach and the pharmacological advancements of pyrimidine moiety in the new era of therapeutics as anti-Alzheimer’s agents.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
CNS & neurological disorders, drug targets - 21(2023), 10, Seite 14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Das, Subham [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011169133 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011169133 | ||
| 003 | DE-627 | ||
| 005 | 20231128075641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011169133 | ||
| 035 | |a (KFL)prod_DARH_.98638DDB67971FAE1FF504C5B5DD1A2621ED391B | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Das, Subham |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structural Activity Relationship based Medicinal Perspectives of Pyrimidine Derivatives as Anti-Alzheimer's Agents: A Comprehensive Review |c Subham Das, Saleem Akbar, Bahar Ahmed, Rikeshwar Prasad Dewangan, Ashif Iqubal, Faheem Hyder Pottoo, Alex Joseph |
| 264 | 1 | |c 2023 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Pyrimidine is an aromatic and heterocyclic organic compound containing a 6-membered ring consisting of four carbon and two nitrogen atoms on alternative positions. Pyrimidine scaffolds described their existence in the medicinal chemist’s cause for their synthesizing practicability and nonpoisonous nature. However, the reason behind neurological disorders is still an open challenge for scientific research and development organizations. Efficacy voids are widespread before researchers, despite high throughput research in the field of anti-Alzheimer's drugs.Researchers have constantly investigated all the probabilities for restraining the unwanted adverse effects of the anti-Alzheimer’s agents and are focusing more extensively to rehabilitate neurological disorders. The scientific literature on drug development has been an aspiration to medicinal chemists and other researchers to facilitate further research. Therefore, this review emphasizes the structure-activity relationship (SAR) based approach and the pharmacological advancements of pyrimidine moiety in the new era of therapeutics as anti-Alzheimer’s agents | ||
| 700 | 1 | |a Akbar, Saleem |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Bahar |e verfasserin |4 aut | |
| 700 | 1 | |a Dewangan, Rikeshwar Prasad |e verfasserin |4 aut | |
| 700 | 1 | |a Iqubal, Ashif |e verfasserin |4 aut | |
| 700 | 1 | |a Pottoo, Faheem Hyder |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, Alex |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS & neurological disorders, drug targets |d Saif Zone, Sharjah, U.A.E. : [Verlag nicht ermittelbar], 2006 |g 21(2023), 10, Seite 14 |h Online-Ressource |w (DE-627)KFL000006513 |w (DE-600)2254204-8 |w (DE-576)273891022 |x 1996-3181 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:10 |g pages:14 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5273&volume=21&issue=10&spage=926 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 10 |h 14 | ||